ARTICLE | Strategy
Dealing Denali
Swarm of deals add pipeline and yield clues to Denali's CNS playbook
September 12, 2016 7:00 AM UTC
Denali Therapeutics Inc.'s recent unveiling of 11 deals provides the first glimpse of how the company plans to deploy its nearly $350 million war chest to target neurodegenerative diseases.
The company has previously said it is focusing on "triggers" and "effectors" of neurodegenerative diseases including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis...